CO5650255A2 - Combinacion que comprenden n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridin-3-sulfonamida y un analogo de lhrh y/o un bifosfonato - Google Patents

Combinacion que comprenden n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridin-3-sulfonamida y un analogo de lhrh y/o un bifosfonato

Info

Publication number
CO5650255A2
CO5650255A2 CO06020457A CO06020457A CO5650255A2 CO 5650255 A2 CO5650255 A2 CO 5650255A2 CO 06020457 A CO06020457 A CO 06020457A CO 06020457 A CO06020457 A CO 06020457A CO 5650255 A2 CO5650255 A2 CO 5650255A2
Authority
CO
Colombia
Prior art keywords
lhrh
oxadiazol
sulfonamide
phenyl
analog
Prior art date
Application number
CO06020457A
Other languages
English (en)
Inventor
Neil Gallagher
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29226541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5650255(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5650255A2 publication Critical patent/CO5650255A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Una combinación que comprende N-(3-metoxi-5-metilpirazin-2-il)2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida, o su sal farmacéuticamente aceptable, y un análogo de LHRH.2.- Una combinación que comprende N-(3-metoxi-5-metilpirazin-2-il)2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida, o su sal farmacéuticamente aceptable, y un bifosfonato.3.- Una combinación que comprende N-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida, o su sal farmacéuticamente aceptable, un análogo de LHRH y un bifosfonato.4.- Una combinación de acuerdo con las reivindicaciones 1 ó 3, en donde el análogo de LHRH es un agonista de LHRH.5.- Una combinación de acuerdo con la reivindicación 4 en donde el agonista de LHRH se selecciona de leuprorelina, buserelina, triptorelina y goserelina.6.- Una combinación de acuerdo con las reivindicaciones 4 ó 5, en donde el agonista de LHRH es goserelina.7.- Una combinación de acuerdo con las reivindicaciones 1 ó 3, en donde el análogo de LHRH es un antagonista de LHRH.8.- Una combinación de acuerdo con la reivindicación 7, en donde el antagonista de LHRH se selecciona de antide, abarelix, antarelix, cetrorelix, azaline o ganirelix.
CO06020457A 2003-09-05 2006-03-01 Combinacion que comprenden n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridin-3-sulfonamida y un analogo de lhrh y/o un bifosfonato CO5650255A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320806.3A GB0320806D0 (en) 2003-09-05 2003-09-05 Therapeutic treatment

Publications (1)

Publication Number Publication Date
CO5650255A2 true CO5650255A2 (es) 2006-06-30

Family

ID=29226541

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06020457A CO5650255A2 (es) 2003-09-05 2006-03-01 Combinacion que comprenden n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridin-3-sulfonamida y un analogo de lhrh y/o un bifosfonato

Country Status (30)

Country Link
US (2) US20060287241A1 (es)
EP (2) EP1663236B1 (es)
JP (1) JP2007504265A (es)
KR (1) KR20060069857A (es)
CN (1) CN1878555A (es)
AR (1) AR045572A1 (es)
AT (1) ATE424206T1 (es)
AU (1) AU2004269956B2 (es)
BR (1) BRPI0413974A (es)
CA (1) CA2537096A1 (es)
CO (1) CO5650255A2 (es)
CY (1) CY1110315T1 (es)
DE (1) DE602004019795D1 (es)
DK (1) DK1663236T3 (es)
ES (1) ES2321620T3 (es)
GB (1) GB0320806D0 (es)
HK (1) HK1090294A1 (es)
HR (1) HRP20090229T1 (es)
IL (1) IL173817A (es)
IS (1) IS8365A (es)
MX (1) MXPA06002485A (es)
NO (1) NO20061051L (es)
NZ (1) NZ545468A (es)
PL (1) PL1663236T3 (es)
PT (1) PT1663236E (es)
RU (1) RU2398588C2 (es)
SI (1) SI1663236T1 (es)
TW (1) TW200509934A (es)
WO (1) WO2005023264A1 (es)
ZA (1) ZA200601871B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
PL2209501T3 (pl) 2007-10-12 2012-03-30 Astrazeneca Ab Kompozycja zibotentanu zawierająca mannitol i celulozę mikrokrystaliczną
PT2252627T (pt) 2008-01-24 2017-07-24 Esperance Pharmaceuticals Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
KR102460297B1 (ko) 2012-10-30 2022-10-28 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) * 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4431635A (en) 1979-06-13 1984-02-14 Coy David Howard LH-RH Antagonists
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4547370A (en) 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4801577A (en) 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4935491A (en) 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5300492A (en) 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US4992421A (en) 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5171635A (en) 1990-10-10 1992-12-15 E. I. Du Pont De Nemours And Company Composite wire construction
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
US5413990A (en) 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
WO1997014697A1 (en) 1995-10-19 1997-04-24 Takeda Chemical Industries, Ltd. Thienopyridine derivatives as gonadotropin releasing hormone antagonists
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100566D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
MXPA03010007A (es) * 2001-05-02 2004-02-12 Novartis Ag USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
SE0101692D0 (sv) 2001-05-14 2001-05-14 Astrazeneca Ab Compounds
US20050215528A1 (en) * 2001-08-10 2005-09-29 Shuichi Furuya Gnrh agonist combination drugs
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
TW200509934A (en) 2005-03-16
DK1663236T3 (da) 2009-05-25
EP2018865A3 (en) 2009-11-18
JP2007504265A (ja) 2007-03-01
BRPI0413974A (pt) 2006-10-31
AR045572A1 (es) 2005-11-02
CN1878555A (zh) 2006-12-13
CA2537096A1 (en) 2005-03-17
RU2006110736A (ru) 2007-10-10
US20060287241A1 (en) 2006-12-21
NO20061051L (no) 2006-04-03
KR20060069857A (ko) 2006-06-22
WO2005023264A1 (en) 2005-03-17
ES2321620T3 (es) 2009-06-09
NZ545468A (en) 2009-03-31
HK1090294A1 (en) 2006-12-22
CY1110315T1 (el) 2015-01-14
ZA200601871B (en) 2007-05-30
IS8365A (is) 2006-03-20
IL173817A0 (en) 2006-07-05
EP1663236B1 (en) 2009-03-04
GB0320806D0 (en) 2003-10-08
PT1663236E (pt) 2009-04-24
EP2018865A2 (en) 2009-01-28
PL1663236T3 (pl) 2009-07-31
US20100004181A1 (en) 2010-01-07
EP1663236A1 (en) 2006-06-07
IL173817A (en) 2011-03-31
RU2398588C2 (ru) 2010-09-10
AU2004269956B2 (en) 2008-04-17
DE602004019795D1 (de) 2009-04-16
HRP20090229T1 (en) 2009-05-31
AU2004269956A1 (en) 2005-03-17
MXPA06002485A (es) 2006-06-20
SI1663236T1 (sl) 2009-06-30
ATE424206T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
CO5650255A2 (es) Combinacion que comprenden n-(3-metoxi-5-metilpirazin-2-il)-2-(4-(1,3,4-oxadiazol-2-il)fenil)piridin-3-sulfonamida y un analogo de lhrh y/o un bifosfonato
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
MXPA03011625A (es) Estacion de carnada para roedores.
ATE359805T1 (de) Formulierung zur verzögerten freisetzung von peptidagonisten und -analoga des gnrh
ATE229976T1 (de) Gnrh antagonisten
DK1435910T3 (da) Nye cyclosporinanaloge mikroemulsionsprækoncentrater
NO900888D0 (no) Effektive antagonister til hormonet som frigjoer luteiniserende hormon, og som frigjoer ubetydelig histamin.
WO2007000036A3 (en) Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases
NO954722L (no) Peptid inhibitorer med urokinase reseptoraktivitet
CA2412759A1 (en) Injectable solution of an lhrh antagonist
ATE414510T1 (de) Verwendung von 13-hode als regulator der vaskulären biokompatibilität und als inhibitor der zellulären hyperplasie
CO5580793A2 (es) Solucion para inyectar que comprende un antagonista lhrh
ATE313557T1 (de) Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung
ATE400287T1 (de) Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit
ES2168692T3 (es) Apisonadora vibradora.
DE60026347D1 (de) Anwendung von nicht menschliches SHIP2 'Knock-out' Säugtiere
EA200401619A1 (ru) Способ управляемой гиперстимуляции яичников и фармацевтический набор для использования в таком способе
PE20010578A1 (es) Mesoprogestinas (modulares de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
FR2804475B1 (fr) Dispositif d'injection de gaz naturel dans la chambre de combustion d'un cylindre
EE200300047A (et) Mittepeptiidsed CCR1-retseptori antagonistid kombinatsioonis tsüklosporiiniga A südametransplantaadi hülgamisreaktsiooni raviks
DE50010124D1 (de) Tensidhaltige reinigungsmittel mit enzym-inhibitoren
UY31042A1 (es) Combinación de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca
UY24556A1 (es) Comprimidos con alto contenido de famciclovir
EP1662007A4 (en) PROPHYLACTIC PRODUCT OR REMEDY FOR INFLAMMATORY INTESTINAL DISEASE CONTAINING ANTI-CD81 ANTIBODY AS ACTIVE INGREDIENT
ATE369129T1 (de) Kombination eines atp-competitiven inhibitors der bcr/abl kinase und eines tyrphostin analogen

Legal Events

Date Code Title Description
FC Application refused